Hyponatremia associated with Ipilimumab-induced hypophysitis

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 374-377

  Barnard, Zachary R ^a   Walcott, Brian P ^a   Kahle, Kristopher T ^a   Nahed, Brian V ^a   Coumans, Jean Valery ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibodies; Inappropriate ADH syndrome; Melanoma; Monoclonal; Pituitary gland

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; IPILIMUMAB; PREDNISONE; SODIUM; SODIUM CHLORIDE; THYROTROPIN; THYROXINE;

ADENOHYPOPHYSIS; AGED; ANAMNESIS; ARTICLE; CANCER STAGING; CASE REPORT; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FLUID THERAPY; FREE THYROXINE INDEX; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPEROSMOLARITY; HYPONATREMIA; HYPOPHYSITIS; INAPPROPRIATE VASOPRESSIN SECRETION; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PITUITARY STALK; PRIORITY JOURNAL; RADIOGRAPHY; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TISSUE NECROSIS; URINE OSMOLALITY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MELANOMA; PITUITARY DISEASES;

EID: 84864067813     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9794-7     Document Type: Article

References (19)

1. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541-7.
2. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861-71.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
4. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29-38.
5. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-30. (Pubitemid 350295361)
6. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681-8. (Pubitemid 350206804)
7. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12): 1005-16. (Pubitemid 41660676)
8. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043-53.
9. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-72. (Pubitemid 46789896)
10. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer. 2000;8(3): 192-7. (Pubitemid 30183035)
11. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581-9.
12. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30-5.
13. Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol. 2010;162(Suppl 1):S13-8.
14. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyp-onatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transpl. 2006;21(1): 70-6. (Pubitemid 43057112)
15. Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, et al. Characteristics and mortality of severe hyponatraemia-a hospital-based study. Clin Endocrinol (Oxf). 2006;65(2):246-9. (Pubitemid 44079690)
16. Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine (Baltimore). 1976;55(2):121-9.
17. Diederich S, Franzen N, Bähr V, Oelkers W. Severe hyponatre-mia due to hypopituitarism with adrenal insufficiency: report on 28 cases. Eur J Endocrinol. 2003;148(6):609-17. (Pubitemid 36758290)
18. Rivera J. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary. 2006;9(1):35-45. (Pubitemid 43733081)
19. Abe T. Lymphocytic infundibulo-neurohypophysitis and infun-dibulo- panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol. 2008;25(2):59-66.